MAX Power Begins Historic Drilling of Canada's First-Ever Natural Hydrogen Well GlobeNewswire November 07, 2025 The Lawson Target Exhibits All Five Key Elements for a Potential Natural Hydrogen Accumulation Including Source Rocks, Migration Pathways, Reservoirs, Seals and Traps, Along With a Defined Four-Way Structural Closure MAX Power Saskatchewan Natural Hydrogen Documentary Videohttps://www.maxpowermining.com/NaturalHydrogen-NewEra/ SASKATOON, Saskatchewan, Nov. […]

Dupixent(R) (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review GlobeNewswire November 07, 2025 Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in

Biofrontera Inc. announces sale of license to Xepi(R) Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M GlobeNewswire November 07, 2025 Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in sales-related milestone payments. Transaction further bolsters our cash

Bioprocess Containers Market to Soar from USD 3.12 Billion in 2024 to USD 31.91 Billion by 2034, Driven by the Shift Toward Single-Use Bioprocessing Systems The global bioprocess containers market size is calculated at USD 3.93 billion in 2025 and is expected to reach around USD 31.91 billion by 2034, growing at a CAGR of

Vaxart to Host Upcoming Conference Calls GlobeNewswire November 07, 2025 Third quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET Stockholder fireside chat to be held on November 18 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) — Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”) today

Pelthos Therapeutics Acquires Xepi(R) (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing GlobeNewswire November 07, 2025 Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI(TM) Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in antibiotic-resistant skin infections caused by staph and strep

Black Friday Starts Early at Curacao: Three Weeks of Massive Savings You Can't Miss Shoppers Get a Head Start on Holiday Savings with Three Weeks of Massive Early Black Friday Deals and Exclusive Curacao Club Discounts GlobeNewswire November 07, 2025 LOS ANGELES, Nov. 07, 2025 (GLOBE NEWSWIRE) — Curacao, one of the largest Hispanic-focused retailers

Karbon-X Expands Blue Carbon Leadership with New Restoration Project in Guinea New initiative in the Konkoure Delta builds on Senegal's success, advancing coastal restoration, biodiversity, and community resilience across West Africa. GlobeNewswire November 07, 2025 CONAKRY, Guinea, Nov. 07, 2025 (GLOBE NEWSWIRE) — Building on the success of its 7,000-hectare mangrove reforestation project in Senegal–which

AirJoule Technologies Schedules Release of Third Quarter 2025 Results and Conference Call GlobeNewswire November 07, 2025 RONAN, Mont., Nov. 07, 2025 (GLOBE NEWSWIRE) — AirJoule Technologies Corporation (NASDAQ: AIRJ) (“AirJoule Technologies” or the “Company”), a leading platform technology that unleashes the power of water from air, today announced that it will report its third quarter

Dycom Industries, Inc. to Host Fiscal 2026 Third Quarter Results Conference Call GlobeNewswire November 07, 2025 WEST PALM BEACH, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) — Dycom Industries, Inc. (NYSE: DY) will host a conference call to discuss fiscal 2026 third quarter results on Wednesday, November 19, 2025, at 9:00 a.m. ET. Dycom will issue